Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity

This study has been completed.
Information provided by (Responsible Party):
Kuo-Tung Chiang, Beitou Armed Forces Hospital, Taipei, Taiwan Identifier:
First received: June 27, 2011
Last updated: February 23, 2012
Last verified: February 2012
The primary aim of the study is to investigate the efficacy of metformin and topiramate on second-generation antipsychotic-induced obesity. The secondary domain we look at is the adverse effects of both drugs. The investigators hypothesize that metformin and topiramate are effective in treating obesity induced by second-generation antipsychotics.

Condition Intervention
Drug: metformin, topiramate

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity

Resource links provided by NLM:

Further study details as provided by Beitou Armed Forces Hospital, Taipei, Taiwan:

Primary Outcome Measures:
  • The changes in metabolic panel as the primary outcome [ Time Frame: up to six months ]
    Metabolic panel, which includes HDL-C, VLDL, LDL, cholesterol, triglycerides, insulin, leptin, BW, Glucose, blood pressure, and weight(with waist circumference and BMI) will be assessed every month

Secondary Outcome Measures:
  • Number of Participants with Adverse Events (including psychiatric adverse events) as a Measure of Safety and Tolerability [ Time Frame: up to six months ]
    We use Positive and Negative Syndrome Scale, the Hamilton Depression Rating Scale, clinical golbal impression-severity, and the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale every month to investigate the participants' safety and tolerability.

Enrollment: 25
Study Start Date: May 2011
Study Completion Date: January 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: metformin, topiramate Drug: metformin, topiramate
metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks


Ages Eligible for Study:   20 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis: schizophrenia or schizoaffective disorder
  2. Age: 20 to 65
  3. BMI>27
  4. Receiving second-generation antipsychotics(Olanzapine, Clozapine, Quetiapine, Risperidone, Amisulpride, Zotepine)

Exclusion Criteria:

  1. Allergy to metformin or topiramate
  2. Currently taking metformin or topiramate
  3. Currently taking drugs that may interact with topiramate, including carbamazepine, eslicarbazepine, oxcarbazepine, phenobarbital, phenytoin, primidone, amitriptyline, lithium, metformin, propranolol, and sumatriptan.
  4. Being pregnant or planning to become pregnant during the study period,
  5. History of hypertension, DM, liver or renal function impairment, cardiovascular disease, CVA, or neurological disorders
  6. History of hypoglycemia
  7. History of suicidal attempt
  8. Current scale of Hamilton Depression Rating Scale>8
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01384279

Beitou Armed Forces Hospital
Taipei, Taiwan, 11243
Sponsors and Collaborators
Beitou Armed Forces Hospital, Taipei, Taiwan
Principal Investigator: Chiang Kuo-Tung, M.D. Department of Psychiatry, Beitou Armed Forces Hospital, Taipei, Taiwan
  More Information

Responsible Party: Kuo-Tung Chiang, Beitou Armed Forces Hospital, Beitou Armed Forces Hospital, Taipei, Taiwan Identifier: NCT01384279     History of Changes
Other Study ID Numbers: BT-099-03
Study First Received: June 27, 2011
Last Updated: February 23, 2012

Keywords provided by Beitou Armed Forces Hospital, Taipei, Taiwan:
metabolic syndrome

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms
Antipsychotic Agents
Hypoglycemic Agents
Physiological Effects of Drugs
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Neuroprotective Agents
Protective Agents
Anti-Obesity Agents processed this record on April 28, 2017